1.Department of Critical Care Medicine,Panyu Maternal and Child Care Service Centre of Guangzhou,Panyu District He Xian Memorial Hospital,Guangdong Province,Guangzhou 511400,China;
2.Department of Radiology,Panyu Maternal and Child Care Service Centre of Guangzhou,Panyu District He Xian Memorial Hospital,Guangdong Province,Guangzhou 511400,China;
3.Department of Cardiovascular Medicine,Panyu Maternal and Child Care Service Centre of Guangzhou,Panyu District He Xian Memorial Hospital,Guangdong Province,Guangzhou 511400,China
Abstract：Objective To explore the effect of low-dose Colchicine on myocardial fibrosis in patients with primary hypertension complicated with hyperuricemia.Methods A total of 100 patients with primary hypertension complicated with hyperuricemia treated in Panyu Maternal and Child Care Service Centre of Guangzhou from January 2017 to June 2020 were selected as the research objects.According to random number table method,they were divided into control group (n=50) and observation group (n=50).Both groups were given routine antihypertensive and uric acid treatment.On this basis,the observation group was treated with low-dose Colchicine and the control group was treated with placebo.The levels of uric acid,high sensitivity C-reactive protein (hs-CRP) and related indexes of myocardial fibrosis(osteopontin [OPN],transforming growth factor β1 [TGF-β1],plasminogen activator blocking factor-1 [PAI-1],type Ⅰprocollagen carboxy terminal peptide [PⅠCP],type Ⅰprocollagen carboxy terminal cross-linking peptide [CⅠTP],type Ⅲprocollagen amino terminal peptide [PⅢNP]) were compared between the two groups before and after treatment.The left ventricular end diastolic diameter (LVEDD),left ventricular end systolic diameter (LVESD) and left ventricular ejection fraction (LVEF) were compared between the two groups before and after treatment.Results After 6 months and 12 months of treatment,uric acid and hs-CRP in the observation group were lower than those in the control group,with statistically significant differences (P＜0.05).After 12 months of treatment,the levels of OPN,TGF-β1,PAI-1,PⅠCP,CⅠTP and PⅢNP in the observation group were lower than those in the control group,with statistically significant differences (P＜0.05).After 12 months of treatment,LVEDD and LVESD in the observation group were lower than those in the control group,and LVEF was higher than that in the control group,with statistically significant differences (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Low-dose Colchicine can effectively delay myocardial fibrosis in patients with primary hypertension complicated with hyperuricemia.It has high security.
Demidowich AP，Davis AI，Dedhia N，et al.Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation[J].Med Hypotheses，2016，92：67-73.
[6]
Wang Y，Viollet B，Terkeltaub R，et al.AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages[J].Ann Rheum Dis，2016，75（1）：286-294.
Pei L，Shu S，Wang X，et al.Effect of chrysanthemum extract on myocardial fibrosis in rats with renovascular hypertension[J].J Tradit Chin Med，2019，39（4）：96-103.
[12]
Rosin NL，Sopel MJ，Falkenham A，et al.Disruption of Collagen Homeostasis Can Reverse Established Age-Related Myocardial Fibrosis[J].Am J Pathol，2015，185（3）：631-642.
Engebretsen KV，Skardal K，Bjornstad S，et al.Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16，an orally active inhibitor of ALK5[J].J Mol Cell Cardiol，2014，26：148-157.
京公网安备 11010502046607号